The slide to be stained for
ER comprised the
following 7 tissues:
|
No. |
Tissue |
ER
extension* |
ER intensity* |
|
1. |
Uterine cervix
|
80 - 90 % |
Moderate to strong |
|
2. |
Breast lobular carcinoma |
60 - 80 % |
Weak to moderate |
|
3. |
Breast ductal carcinoma |
10 - 30 % |
Weak |
|
4. |
Breast ductal carcinoma |
Negative |
Negative |
|
5. |
Breast ductal carcinoma |
10 - 30 % |
Weak |
|
6. |
Breast ductal carcinoma |
60 - 80 % |
Weak to moderate |
|
7. |
Breast ductal carcinoma |
50 - 70 % |
Moderate to strong |
*ER-status and staining pattern as
characterized by NordiQC reference laboratories using the mAb clone
6F11 and the rmAb clone SP1.
All tissues were fixed in 10% neutral buffered formalin for 24 – 48
hours and processed according to
Yaziji et al. (1).
Criteria for assessing an ER staining as optimal included:
-
A moderate to strong, distinct nuclear staining of
most columnar
and squamous epithelial cells as well as most stromal cells (with
the exception of endothelial and lymphoid cells) in the
uterine cervix.
-
At least a weak to moderate distinct nuclear staining of the
proportion of the neoplastic cells in the breast ductal
carcinomas no. 2, 3, 5 & 6
as indicated above.
-
A strong distinct nuclear staining of the proportion of
the neoplastic cells in the breast ductal carcinoma no. 7 as
indicated above.
-
No nuclear staining in the neoplastic cells in the breast carcinoma
no. 4 and no more than a weak cytoplasmic reaction in cells with a
strong nuclear staining.
A cytoplasmic reaction in the breast ductal carcinoma no. 4 was
accepted when using the mAb clone 1D5, as this did not influence the
interpretation.
197 laboratories participated in this assessment. 67 % achieved a
sufficient mark. In table 1 the antibodies (Abs) used and the marks
given are
summarized.
Table 1.
Abs and
assessment marks
for ER, run B10
|
Concentrated Abs |
N |
Vendor |
Optimal |
Good |
Borderl. |
Poor |
Suff.1 |
Suff. OPS2 |
|
rmAb clone
SP1 |
32 4 1 1 |
NeoMarkers Dako Immunologic
Spring |
20 |
10 |
6 |
2 |
79 % |
79 % |
|
mAb clone 6F11 |
29 2 1 1 |
Novocastra/Leica Vector BioCare
Monosan |
9 |
7 |
8 |
9 |
48 % |
78 % |
|
mAb clone 1D5 |
24 2 2 |
Dako Immunologic
Zytomed |
5 |
3 |
5 |
15 |
29 % |
44 % |
|
mAb clones
1D5+6F11 |
4 |
NeoMarkers |
0 |
1 |
3 |
0 |
- |
- |
|
Ready-To-Use Abs |
|
|
|
|
|
|
|
|
|
rmAb clone SP1,
790-4324/25 |
60 |
Ventana |
56 |
3 |
0 |
1 |
98 % |
98 % |
|
rmAb, clone SP1,
IS/IR151 |
22 |
Dako |
8 |
6 |
5 |
3 |
64 % |
100 % |
|
rmAb clone SP1,
RM-9101-R7 |
4 |
NeoMarkers |
0 |
2 |
1 |
1 |
- |
- |
|
mAb/rmAb clones 6F11+SP1,
PM308 |
1 |
Biocare |
1 |
0 |
0 |
0 |
- |
- |
|
mAb clone 6F11,
PA0151 |
1 |
Novocastra/Leica |
0 |
0 |
0 |
1 |
- |
- |
|
mAb clone 1D5,
IR654 |
1 |
Dako |
0 |
0 |
0 |
1 |
- |
- |
|
mAb clone
1D5, N1575 |
1 |
Dako |
0 |
0 |
0 |
1 |
- |
- |
|
mAb clones 1D5+ER-2-123,
SK310/K4071 |
4 |
Dako |
0 |
2 |
1 |
1 |
- |
- |
|
Total |
197 |
|
99 |
34 |
29 |
35 |
- |
- |
|
Proportion |
|
|
50 % |
17 % |
15 % |
18 % |
67 % |
- |
1) Proportion of sufficient stains
(optimal or good), 2) Proportion of sufficient stains with optimal
protocol settings only, see below.
The following central protocol parameters were used to obtain an
optimal staining:
Concentrated Abs rmAb clone SP1: The protocols giving an optimal result were all
based on heat induced epitope retrieval (HIER) using either
Tris-EDTA/EGTA pH 9 (6/12)*, Target Retrieval Solution (TRS) pH 9
(Dako) (1/4), TRS pH 9 (3-in-1, Dako) (2/4), Cell Conditioning 1
(BenchMark, Ventana) (7/10), Bond Epitope Retrieval Solution 2
(Bond, Leica) (1/1), Bond Epitope Retrieval Solution 1 (Bond, Leica)
(1/1), Diva Decloaker (Biocare) (1/2) or Citrate pH 6 (1/4) as the
retrieval buffer. The mAb was typically diluted in the range of
1:25– 1:200 depending on the total sensitivity of the protocol
employed. Using these protocol settings 30 out of 38 (79 %)
laboratories produced a sufficient staining (optimal or good).
* (number of optimal results/number of laboratories using this
buffer)
mAb clone 6F11: The protocols giving an optimal result were all
based on HIER using either
Tris-EDTA/EGTA pH 9 (4/9), TRS pH 9 (Dako) (1/3), TRS pH 9 (3-in-1,
Dako) (2/4) or Bond Epitope Retrieval Solution 2 (Bond, Leica) (2/6)
as the retrieval buffer. The mAb was typically diluted in the range
of 1:50– 1:100 depending on the total sensitivity of the protocol
employed. Using these protocol settings 14 out of 18 (78 %)
laboratories produced a sufficient staining.
mAb clone 1D5: The protocols giving an optimal result were
all based on HIER using Tris-EDTA/EGTA pH 9
(3/12) or TRS pH 9 (3-in-1, Dako) (2/6) as the retrieval buffer. The
mAb was diluted in the range of 1:35– 1:100 depending on the total
sensitivity of the protocol employed. Using these protocol settings
8 out of 18 (44 %) laboratories produced a sufficient staining.
Ready-To-Use Abs rmAb clone
SP1 (prod. no. 790-4324/25, Ventana): The protocols
giving an optimal result were based on HIER using mild or standard
Cell Conditioning 1, an incubation time of 16-40 min in the primary
Ab and iView (760-091) or UltraView (760-500) as the detection
system with or without amplification. Using these protocol
settings 59 out of 60 (98 %) laboratories produced a sufficient
staining.
rmAb clone SP1 (prod. no. IS/IR151, Dako): The protocols giving an
optimal result were all based on HIER in PT-Link using TRS pH 9 or
TRS pH 9 (3-in-1) for 20 min and an incubation time of 20-30 min in
the primary Ab and EnVision Flex (K8000), Flex+ (K8002) or EnVision
REAL (K5007) as the detection system. Using these protocol settings
all of 11 (100 %) laboratories produced a sufficient staining
(optimal or good). One lab used an incubation time of 32 min, HIER in
standard Cell Conditioning 1 (Benchmark, Ventana) and UltraView
(760-500) as the detection system and produced a staining marked as
optimal.
mAb/rmAb clones 6F11+SP1 (prod. no. PM308, BioCare): The protocol
giving an optimal result was based on HIER using Reveal Decloaker
(Biocare), an incubation time of 45 min in the primary Ab and MACH4
Universal HRP Polymer kit (M4U534) as the detection system.
- - -
The most frequent causes of insufficient
staining reactions were: - Too low concentration of the primary antibody. - Insufficient HIER (use of citrate pH 6.0 and/or too short
efficient heating time). - Less successful performance of the mAb clone 1D5 both as
concentrate and in Ready-To-Use (RTU) formats.
In this assessment the prevalent feature of an insufficient staining
was a generally too weak or false negative
reaction, the latter especially seen in ductal carcinomas no. 3 & 5
(where a weak staining of 10-30% of the neoplastic cells was
expected). This
pattern was seen in 50 out of 64 of the insufficient results (78 %).
Insufficient HIER and/or a too low concentration of the primary Ab
were the most common causes for the insufficient results.
In 10 out of 64 of the insufficient results (16%) both a false
negative and false positive staining was seen, typically due to a
too low concentration of the primary Ab combined with efficient HIER
in an alkaline buffer and the use of a biotin based detection system.
This gave a strong cytoplasmic staining in the lobular carcinoma no.
2 while the nuclei were almost negative complicating the
interpretation. Also a negative reaction was seen in the two
ductal breast carcinomas no. 3 & 5 in these cases.
As observed in the previous assessment for ER, all the 3 most widely
used Abs for ER, the mAb clones 1D5 and 6F11 and the rmAb clone SP1
could be used to obtain an optimal staining. However in this run
B10, the rmAb clone SP1 (both as concentrate and Ready-To-Use) gave
a higher proportion of sufficient results compared to clone 6F11 and in particular to clone 1D5.
It was noteworthy that the RTU systems from Dako
and Ventana for the rmAb clone SP1 gave a significant higher pass
rate (98-100 %) than the pass rate (79 %) when same clone was used
with an in-house procedure, even with optimal
protocol settings.
In table 2 the overall performance of the three most widely used Abs for
ER in the NordiQC assessments is listed.
Table 2. Results for the three most widely used Abs in eight NordiQC ER tests
|
|
All ER
assessments*
All protocol settings |
All ER
assessments*
Optimal protocol settings** |
|
|
Protocols |
Sufficient |
Optimal |
Protocols |
Sufficient |
Optimal |
|
mAb clone
1D5 |
274 |
158 (58%) |
49 (18%) |
145 |
99 (68%) |
49 (34%) |
|
mAb
6F11 |
274 |
198 (72%) |
103 (38%) |
208 |
174 (84%) |
103 (50%) |
|
rmAb
SP1 |
372 |
315 (85%) |
235 (63%) |
340 |
308 (91%) |
235 (69%) |
*Runs 8, 10, 13, B1, B3, B5, B7, B8
and B10. ** HIER settings and dilution
range of the Ab in all assessments giving an optimal result.
As shown in the previous runs, uterine cervix was an
appropriate control for ER
staining: In the optimal protocols almost all the epithelial cells
throughout the layers of the squamous epithelium and in the glands
showed a moderate to strong and distinct nuclear reaction.
This was the 9th assessment of ER in NordiQC. A decrease in the
proportion of sufficient results has been seen in the last two runs
as shown in table 3. The decrease in part is caused by many new
participants in the last two runs and also a more challenging
material.
Table 3:
Proportion of sufficient results for ER in the earlier NordiQC runs
performed

Conclusion The mAb clone 6F11 and in particular the rmAb SP1 were the most
robust Abs for ER. In this assessment the RTU systems for ER based
on the rmAb clone SP1 (Dako and Ventana) gave a higher pass rate for
the demonstration of ER than the in-house protocols. Clone 1D5
constantly shows an inferior performance.
HIER is mandatory, preferable in an alkaline
buffer: A non-biotin based detection system should be used. Uterine cervix is an appropriate control for ER: Both the
epithelial cells and most stromal cells must show a strong distinct
nuclear reaction with minimal cytoplasmic reaction. |